Regions’ capital allocation plan is reasonable and flexible, with 35%-45% allocated to dividends and the next portion of earnings dedicated to internal investments, bolt-on acquisitions over time, and ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.

Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...